Azithromycin distribution and childhood mortality in compliance-related subgroups in Niger: complier average causal effect and spillovers in a cluster-randomized, placebo-controlled trial. (11th September 2021)

• Record Type: Journal Article
• Authors: O'Brien, Kieran S; Arzika, Ahmed M; Maliki, Ramatou; Amza, Abdou; Manzo, Farouk; Mankara, Alio Karamba; Lebas, Elodie; Cook, Catherine; Oldenburg, Catherine E; Porco, Travis C; Arnold, Benjamin F; Bertozzi, Stefano; Keenan, Jeremy D; Lietman, Thomas M
• Is Part Of: International journal of epidemiology. Volume 51:Number 6(2022)
• Page Start: 1775
• Page End: 1784
• Publication Date: 2021-09-11
• Subjects: Azithromycin -- complier average causal effect -- cluster-randomized trial -- mortality -- spillover; Epidemiology -- Periodicals; 614.4
• DOI: 10.1093/ije/dyab198
• Languages: English
• ISSNs: 0300-5771

Abstract

Abstract: Background: Biannual azithromycin distribution to children 1–59 months old reduced all-cause mortality by 18% [incidence rate ratio (IRR) 0.82, 95% confidence interval (CI): 0.74, 0.90] in an intention-to-treat analysis of a randomized controlled trial in Niger. Estimation of the effect in compliance-related subgroups can support decision making around implementation of this intervention in programmatic settings. Methods: The cluster-randomized, placebo-controlled design of the original trial enabled unbiased estimation of the effect of azithromycin on mortality rates in two subgroups: (i) treated children (complier average causal effect analysis); and (ii) untreated children (spillover effect analysis), using negative binomial regression. Results: In Niger, 594 eligible communities were randomized to biannual azithromycin or placebo distribution and were followed from December 2014 to August 2017, with a mean treatment coverage of 90% [standard deviation (SD) 10%] in both arms. Subgroup analyses included 2581 deaths among treated children and 245 deaths among untreated children. Among treated children, the incidence rate ratio comparing mortality in azithromycin communities to placebo communities was 0.80 (95% CI: 0.72, 0.88), with mortality rates (deaths per 1000 person-years at risk) of 16.6 in azithromycin communities and 20.9 in placebo communities. Among untreated children, the incidence rate ratio was 0.91 (95% CI: 0.69, 1.21), with rates of 33.6 in azithromycin communities and 34.4 in placebo communities. Conclusions: As expected, this analysis suggested similar efficacy among treated children compared with the intention-to-treat analysis. Though the results were consistent with a small spillover benefit to untreated children, this trial was underpowered to detect spillovers.